Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Trading 81% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 169.5% with 28.3% net margin
- Revenue declining 16% annually
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $695 million . Key value metrics: P/E ratio 6.8, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Ironwood Pharmaceuticals, Inc. - Class A Common Stock — Fundamental Analysis Summary
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD) is currently trading 81% above its Graham Number of $2.33, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 6.8x.
On financial health, IRWD shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 169.5% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 6.87.
StockPik's composite Value Score for IRWD is 75/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
IRWD reports a high gross margin of 99.2% (sector average: 40.1%) and a strong operating margin of 45.4%.
IRWD shows revenue declining at 16% year-over-year, with earnings growing at 2,629%.